Microbiome venture can start production in Denmark and Switzerland

The Danish Medicines agency has inspected Bacthera, a joint venture between Danish enzyme giant Chr. Hansen and Swiss Lonza, and has authorized the company to start producing bacteria for medical purposes in Denmark. The Swiss health authorities have also given the go-ahead.

Photo: Lonza / PR

Bioscience company Chr. Hansen and Swiss biotech firm Lonza have obtained permission to launch the production of bacteria for pharmaceutical use in their production facilities in Denmark and Switzerland.

Health authorities from Denmark and Switzerland have run inspections and found that the two production facilities are suitable for the production of so-called live bio therapeutics, that is, beneficial bacteria to be used in medication.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs